MedTrace Logo

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC)

NCT05597761 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2025-05-14

No results posted yet for this study

Summary

This multicenter, prospective, non-interventional study aims to evaluate data on humoral and cellular immune response generated within the COVID-19 vaccination standard in immunocompromised patients.

Conditions

  • COVID-19
  • Adult
  • Immunocompromised Patients

Sponsors & Collaborators

  • ZKS Köln

    collaborator OTHER

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • Oliver Cornely, MD

    lead OTHER

Principal Investigators

  • Oliver A. Cornely, Prof. · University Hospital of Cologne, Internal Medicine I

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-15
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05597761 on ClinicalTrials.gov